Trials / Completed
CompletedNCT04603989
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Multiple Ascending Doses Study Following Intravenous Administration in Healthy Chinese Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of HNC042
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HNC042 for Injection | HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg |
| DRUG | Placebo Comparator | Placebo , Intravenous route , multiple ascending doses |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2020-11-13
- Completion
- 2020-11-13
- First posted
- 2020-10-27
- Last updated
- 2023-02-23
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04603989. Inclusion in this directory is not an endorsement.